Desarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus

Claudio F.  Lanata-de las Casas; Lucie  Ecker-Ledesma; Rubelio E.  Cornejo-Cotos; Carlos R.  Celis-Albújar; Carmen del Pilar  Díaz-Parra; Sheby A.  Ricalde-Ponce de León; Omar Flores-Salmón; Mayra Ochoa Porras; Bia Peña-Peralta; Ana I.  Gil-Merino

doi:10.33734/diagnostico.v60i3.305

Autores/as

Claudio F. Lanata-de las Casas Instituto de Investigación Nutricional https://orcid.org/0000-0002-6994-7425
Lucie Ecker-Ledesma Instituto de Investigación Nutricional https://orcid.org/0000-0001-6887-2356
Rubelio E. Cornejo-Cotos Instituto de Investigación Nutricional https://orcid.org/0000-0002-2136-1759
Carlos R. Celis-Albújar Instituto de Investigación Nutricional https://orcid.org/0000-0003-1616-0925
Carmen del Pilar Díaz-Parra Instituto de Investigación Nutricional https://orcid.org/0000-0003-1037-2417
Sheby A. Ricalde-Ponce de León Instituto de Investigación Nutricional https://orcid.org/0000-0002-4345-0461
Omar Flores-Salmón Instituto de Investigación Nutricional https://orcid.org/0000-0003-1883-3572
Mayra Ochoa Porras Instituto de Investigación Nutricional https://orcid.org/0000-0001-8002-3314
Bia Peña-Peralta Instituto de Investigación Nutricional https://orcid.org/0000-0001-5534-3658
Ana I. Gil-Merino Instituto de Investigación Nutricional https://orcid.org/0000-0003-0840-4483

DOI:

https://doi.org/10.33734/diagnostico.v60i3.305

Palabras clave:

SARS-CoV2, COVID-19, coronavirus, vacunas, eficacia, efectividad, variantes de interés, variantes de preocupación

Resumen

La aparición de la pandemia causada por el virus SARS-CoV-2 tomó desprevenido al mundo entero. Sin embargo, la reacción ha sido asombrosa. En poco más de un año de la aparición del virus, se cuenta con cientos de vacunas en desarrollo y varias de ellas vienen siendo aplicadas en casi todo el mundo. En este manuscrito revisamos el estado actual del desarrollo de las vacunas, resaltando aquéllas que cuentan con estudios de Fase III (eficacia) o IV (efectividad). Además, revisamos las variantes de interés y de preocupación del virus SARS-CoV-2 detectadas hasta el momento y qué se sabe sobre de la eficacia de las vacunas contra ellas.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N. Genomic characterization, and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

COVID-19 Dashboard, Center for Systems Science and E n g i n e e r i n g , J o h n s H o p k i n s U n i v e r s i t y . https://coronavirus.jhu.edu/map.html.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 ; 383 ( 20 ) : 1920 - 1931 . doi: 10.1056/NEJMoa2022483.

World Health Organization. Research and Development Blue Print. COVID- 19 vaccine tracker and landscape. 04 jun 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid- 19-candidate-vaccines.

Food and Drug Administration. Moderna COVID-19 vaccine Emergency Use Authorization. Siver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020. h t t p s / / w w w. f d a . g o v / e m e r g e n c y - p r e p a r e d n e s s - a n d - response/coronvarus-disease-2019-covid-19/Moderna-covid-19- vaccine.

Food and Drug Administration. Pfizer COVID-19 vaccine Emergency Use Authorization. Siver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020. h t t p s / / w w w. f d a . g o v / e m e r g e n c y - p r e p a r e d n e s s - a n d - response/coronvarus-disease-2019-covid-19/pfizer-biontech-covid- 19-vaccine.

UK Medicines & Healthcare products Regulatory Agency. Regulatory approval of COVID-19 Vaccine AstraZeneca. https://assets.publishing.service.gov.uk/government/uploads/system/u ploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_A straZeneca_23.02.20.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 10: NEJMoa2034577. Published online 2020 Dec 10. doi: 10.1056/NEJMoa2034577.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020 Dec 30: NEJMoa2035389. Published online 2020 Dec 30. doi: 10.1056/NEJMoa2035389

Dagan N, Barda N, Kepten E, Miron O, Shay-Perchik MA, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 Feb 24: NEJMoa2101765. Published online 2021 Feb 24. doi: 10.1056/NEJMoa2101765.

Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a p r o s p e c t i v e , m u l t i c e n t r e , c o h o r t s t u d y. L a n c e t . 2021;397(10286):1725-1735. Published online 2021 Apr 23. doi: 10.1016/S0140-6736(21)00790-X.

Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine - United States, September 6, 2020 - May 1, 2021. MMWR Morb Mortal Wkly Rep. ePub: 8 June 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7023e2.

Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid- 19 Vaccine in Adolescents. N Engl J Med. 2021 May 27: NEJMoa 2107456 . Published online 2021 May 27 . doi: 10.1056/NEJMoa2107456.

Kremsner P, Mann P, Bosch J, Fendel R, Gabor JJ, Kreidenweiss A, et al. Phase I assessment of the safety and immunogenicity of an mRNA

- lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. MedRxiv preprint. Doi:10.1101/2020.11.09.20228551.

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. Online first. JAMA. 2021; doi: 10.1001/jama.2021.8565.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 ; 397 ( 10269 ) : 99 - 111 . doi: 10 . 1016 / S 0140 - 6736(20)32661-1. Correction in: Lancet. 2021;397(10269):98.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275): 671-681. Published online 2021 Feb 2. doi: 10.1016/S0140-6736(21)00234-8. Correction in: Lancet. 2021 20-26 February; 397(10275): 670.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. On-line first. Apr 21, 2021. DOI: 10.1056/NEJMoa2101544.

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK p h a s e 3 t r i a l . P r e s s r e l e a s e , J a n u a r y 2 8 , 2 0 2 1 (https://ir.novavax.com/nes-releases/news-release-details/novavax- covid-19-vaccine-demostrates-893-efficacy-uk-phase-3).

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the

B.1.351 Variant. N Engl J Med. 2021; 384(20):1899-1909. Published online 2021 May 6. doi: 10.1056/NEJMoa2103055.

CDC SARS-CoV-2 Variant Classifications and Definitions. Update June 8 , 2021 . h t t ps:// www. cdc. gov/ coronavirus/ 2019 - n c o v / v a r i a n t s / v a r i a n t - info.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fco ronavirus% 2 F 2019 - ncov% 2 Fcases- updates% 2 Fvariant- surveillance%2Fvariant-info.html.

Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 Jun 3 doi: 10.1016/S0140-6736(21)01290-3 [Epub ahead of print].

Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B1.1.7 and B.1.351 variants. N Engl J Med. 2021 May 5: NEJMc2104974. Published online 2021 May 5. doi: 10.1056/NEJMc2104974.

Romero PE, Davila-Barclay A, Gonzales L, Salvatierra G, Cuicapuza D, Solis L, Maturrano L, Tsukayama P. Novel sublineage within B.1.1.1 currently expanding in Peru and Chile, with a convergent deletion in the ORF1a gene (A3675-3677) and a novel deletion in the spike gene (A246-252, G75V, T76I, L452Q, F490S, T859N). https://virological.org/t/novel-sublineage-within-b-1-1-1-currently- expanding-in-peru-and-chile-with-a-convergent-deletion-in-the- orf1a-gene-3675-3677-and-a-novel-deletion-in-the-spike-gene-246- 252-g75v-t76i-l452q-f490s-t859n/68